Orforglipron: How This Oral GLP-1 Could Change Weight Loss in the UK

As new weight loss treatments are developed, it’s easy to feel overwhelmed by the number of options emerging and how each one works. In this blog post, we’ll take a closer look at Orforglipron, a new weight loss pill, and explore how it works and its potential role in obesity care.

Article Summary:

• Orforglipron is a new, once-daily oral GLP-1 medication currently under development by Eli Lilly for weight loss and type 2 diabetes.
• Orforglipron reduces appetite, improves blood sugar control, and slows gastric emptying. Clinical trials show participants lost an average of 11% of body weight over 72 weeks, with additional benefits for heart health. In trials, side effects have been found to be generally mild and similar to other GLP-1s.
• Orforglipron is not yet approved or available for sale. Any provider claiming to sell it is not legitimate. Regulatory approval is expected as early as 2026, following successful Phase 3 trials.

What is Orforglipron?

Orforglipron is an experimental weight loss medication that is currently being developed by Eli Lily (the same company that manufactures Mounjaro). It is a nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it belongs to the same class of medications as other popular weight loss treatments like Wegovy (semaglutide) and Mounjaro (tirzepatide). [1]

But, there is one key difference that sets Orforglipron apart from other GLP-1s. It is taken as a once-daily oral pill rather than as a weekly injection, making it a great option for patients who find needles intimidating or for those who travel frequently.

This difference is also reflected on a molecular level because, unlike medications such as Wegovy and Mounjaro, Orforglipron isn't made from peptides (protein-like building blocks). Instead, it's a smaller type of molecule. This makes a big difference, as peptide medications get broken down in the stomach, so they have to be given by injection. Orforglipron, on the other hand, can survive digestion, which means it can be taken as a pill. [2]

How Does Orforglipron Work?

Orforglipron works in the same way as other GLP-1 receptor agonists, by mimicking naturally occurring gut hormones after eating.

Here’s how it works on different parts of your body to promote weight loss:

• Regulates appetite by targeting the reward centre in your brain to increase feelings of fullness, reduce appetite, and curb food cravings. [3]
• Helps keep blood sugar levels steady by helping your body release the hormone that lowers blood sugar (insulin) and lowering the hormone that raises it (glucagon). This can prevent spikes and drops that often cause cravings. [3]
• Slows down how fast your stomach empties (gastric emptying), so you feel full for longer. [3]

Clinical Trials and Efficacy

Impact on Weight Management

In studies, people taking the highest dose of Orforglipron lost an average of about 11% of their body weight over 72 weeks, demonstrating its effectiveness as a tool for weight management. [3]

Impact on Blood Sugar

Clinical trials have also shown that Orforglipron helps lower blood sugar levels, which supports better overall type 2 diabetes control. [3]

Impact on Heart Health

Research also suggests it can improve factors like blood pressure and cholesterol which are all important for reducing the risk of heart disease. [3]

Side Effects and Safety

In clinical trials, the most common side effects were mild to moderate digestive events such as diarrhoea, nausea, constipation and abdominal pain, meaning the side effect profile is similar to other GLP-1 medications like Mounjaro. [1]

Dosage and Administration

Orforglipron is taken as a once-daily oral pill and can be taken with or without food, making it a convenient option for patients who find injectable medicaion difficult to fit into their lifestyle.

There is currently no approved dose for Orforglipron, but in clinical trials, participants were randomly assigned to receive Orforglipron at one of three doses (12, 24, 36 mg). [3]

Availability and Cost of Orforglipron

Orforglipron is not currently licensed anywhere and is therefore not available for purchase. However, the good news is that Phase 3 trials for Orforglipron have successfully concluded, meaning that Eli Lilly can now submit this treatment for regulatory review by the MHRA in the United Kingdom and the FDA in the United States. If the regulatory review process goes well, Orforglipron could be launched globally as early as 2026. [4]

This means if you see any providers claiming to sell Orforglipron, it is not a legitimate product as it is not yet licensed anywhere in the world.

Ready to Start Your Weight Loss Treatment?

At MedExpress, we’ll help determine which medication is best suited to your needs, based on your medical history and weight loss goals. Learn more about your options here.

References:

1. What is Orforglipron? [Internet]. Drugs.com. Available from: https://www.drugs.com/medical-answers/what-orforglipron-3574271/
2. Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. 2025 Jun 21;
3. Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025 Sep 16. doi: 10.1056/NEJMoa2511774. Epub ahead of print. PMID: 40960239.
4. Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity | Eli Lilly and Company [Internet]. Eli Lilly and Company. 2024. Available from: https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial